Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Хронический гепатит В при ревматических заболеваниях: вопросы скрининга и реактивации инфекции
Гриднева Г.И., Белов Б.С., Аронова Е.С. Хронический гепатит В при ревматических заболеваниях: вопросы скрининга и реактивации инфекции. Терапевтический архив. 2024;96(5):523–530.
DOI: 10.26442/00403660.2024.05.202707
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/00403660.2024.05.202707
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
Gridneva GI, Belov BS, Aronova ES. Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(5):523–530.
DOI: 10.26442/00403660.2024.05.202707
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Пациенты с ревматическими заболеваниями, инфицированные вирусом гепатита В (hepatitis B virus – HBV), трудны для курации вследствие не только наличия факторов риска развития и быстрого прогрессирования цирроза печени, но и вероятности реактивации данной инфекции. Несмотря на достигнутые успехи в борьбе с HBV, вирус не может быть полностью побежден в связи с имеющимися скрытыми формами течения болезни, ускользающими из поля зрения ревматолога и инфекциониста. В статье на основании результатов анализа актуальных публикаций представлено обоснование полного иммунологического скрининга пациентов с ревматическими заболеваниями при назначении антиревматической терапии. Затронуты вопросы роли коронавирусной инфекции в обострении хронического вирусного гепатита В, противовирусной профилактики и мониторинга, представлена классификация антиревматических препаратов по степени риска реактивации HBV с учетом новейших данных.
Ключевые слова: иммуносупрессивная терапия, антиревматические препараты, хронический вирусный гепатит В, поверхностный антиген вируса гепатита В, скрининг, реактивация, профилактика
Ключевые слова: иммуносупрессивная терапия, антиревматические препараты, хронический вирусный гепатит В, поверхностный антиген вируса гепатита В, скрининг, реактивация, профилактика
________________________________________________
Patients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of this infection. Despite the successes achieved in the fight against HBV, the virus cannot be completely defeated due to the presence of hidden forms of the disease, escaping the field of vision of a rheumatologist and an infectionist. Based on the results of the analysis of current publications, the paper presents the rationale for a complete immunological screening of patients with rheumatic diseases when prescribing antirheumatic therapy. The issues of the role of COVID-19 in the exacerbation of chronic viral hepatitis B, antiviral prevention and monitoring are discussed, the classification of antirheumatic drugs according to the risk of HBV reactivation is presented.
Keywords: immunosuppressive therapy, antirheumatic drugs, chronic viral hepatitis B, HBSAg, screening, reactivation, prevention
Полный текст
Список литературы
1. Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol. 2022;49(1):1-4. DOI:10.3899/jrheum.211000
2. Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2023;43(3):523-31. DOI:10.1007/s00296-022-05169-2
3. О Всемирном дне борьбы с вирусными гепатитами: информация Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 28.07.2022. Режим доступа: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Ссылка активна на 29.04.2023 [O Vsemirnom dne bor'by s virusnymi gepatitami: informatsiia Federal'noi sluzhby po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiia cheloveka ot 28.07.2022. Available at: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Accessed: 29.04.2023 (in Russian)].
4. Каратеев А.Е., Гонтаренко Н.В., Цурган А.В., и др. Вирусные гепатиты B и C как коморбидная патология при ревматических заболеваниях: анализ данных клиники ФГБНУ НИИР им. В.А. Насоновой за 4 года. Научно-практическая ревматология. 2016;54(3):318-23 [Karateev AE, Gontarenko NV, Tsurgan AV, et al. Viral hepatitis B and C as comorbidity in rheumatic diseases: Analysis of the data of the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. Rheumatology Science and Practice. 2016;54(3):318-23 (in Russian)]. DOI:10.14412/1995-4484-2016-318-323
5. Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020;8(11). DOI:10.3390/microorganisms8111792
6. Makvandi M, Noormandi Pour S, Teimoori A, et al. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran. Asian Pac J Cancer Prev. 2022;23(6):1921-6. DOI:10.31557/APJCP.2022.23.6.1921
7. Lo Presti A, Ceccarelli F, Dorrucci M, et al. Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus. New Microbiol. 2022;45(4):296-303.
8. Min Y, Wei X, Xia X, et al. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023;14:1141956. DOI:10.3389/fimmu.2023.1141956
9. Ramsey SD, Unger JM, Baker LH, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497-505. DOI:10.1001/jamaoncol.2018.6437
10. Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-53. DOI:10.1136/ard-2022-223335
11. Padda IS, Bhatt R, Parmar M. Upadacitinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
12. Lin TC, Hashemi N, Kim SC, et al. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2018;70(1):30-8. DOI:10.1002/acr.23241
13. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. DOI:10.1002/hep.29800
14. Fujita M, Sugiyama M, Sato Y, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat.
2018;25(11):1312-20. DOI:10.1111/jvh.12933
15. Mohareb AM, Patel NJ, Fu X, et al. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2022;49(1):104-9. DOI:10.3899/jrheum.210257
16. Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8. DOI:10.1016/j.jmii.2017.10.002
17. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3. DOI:10.1053/j.gastro.2014.10.038
18. Zhou Q, Zhang Q, Wang K, et al. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacol Res. 2022;178:106181. DOI:10.1016/j.phrs.2022.106181
19. Verdelli A, Corrà A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:941003. DOI:10.3389/fmed.2022.941003
20. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-75. DOI:10.1007/s10067-012-1988-2
21. Kalyoncu U, Yonem O, Calguneri M, et al. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatol Int. 2009;29(7):777-80. DOI:10.1007/s00296-008-0790-6
22. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36(6):1188-94. DOI:10.3899/jrheum.081246
23. Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021;24(11):1362-9. DOI:10.1111/1756-185X.14217
24. Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med. 2021;10(12). DOI:10.3390/jcm10122564
25. Xuan D, Yu Y, Shao L, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577-86. DOI:10.1007/s10067-013-2450-9
26. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immuno- suppressive drug therapy. Gastroenterology. 2015;148(1):215-9;quiz e16-7. DOI:10.1053/j.gastro.2014.10.039
27. Zhong Z, Liao W, Dai L, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis. 2022;81(4):584-91. DOI:10.1136/annrheumdis-2021-221650
28. Гриднева Г.И., Белов Б.С., Аронова Е.С. Хронический вирусный гепатит В и ревматические болезни: современный взгляд на проблему. Медицинский алфавит. 2022;29:20-8 [Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: modern view on problem. Medical Alphabet. 2022;29:20-8 (in Russian)]. DOI:10.33667/2078-5631-2022-22-20-28
29. Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780-2. DOI:10.1136/annrheumdis-2017-211322
30. Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1). DOI:10.1136/rmdopen-2019-001095
31. Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases. 2022;10(1):12-22. DOI:10.12998/wjcc.v10.i1.12
32. Lin YC, Chen YJ, Lee SW, et al. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med. 2021;10(15). DOI:10.3390/jcm10153296
33. Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98(9):829-34. DOI:10.2340/00015555-2989
34. Kuo MH, Tseng CW, Lu MC, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;66(11):4026-34. DOI:10.1007/s10620-020-06725-1
35. Lin WT, Chen YM, Chen DY, et al. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75. DOI:10.1177/0961203317711009
36. Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. DOI:10.1177/1759720X20912646
37. Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11(2):e780. DOI:10.1002/iid3.780
38. Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021;9(21):5769-81. DOI:10.12998/wjcc.v9.i21.5769
39. Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670-89. DOI:10.1016/j.jhep.2022.07.003
40. Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015;14(6):979-85. DOI:10.1517/14740338.2015.1031743
41. Koutsianas C, Hadziyannis E, Thomas K, et al. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021;28(12):1710-8. DOI:10.1111/jvh.13610
42. Kuo MH, Tseng CW, Lee CH, et al. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep. 2020;10(1):2456. DOI:10.1038/s41598-020-59406-4
43. Lan TY, Lin YC, Tseng TC, et al. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut Liver. 2023;17(2):288-98. DOI:10.5009/gnl210551
44. Ridola L, Zullo A, Laganà B, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57(3):244-8. DOI:10.4415/ANN_21_03_08
45. Гриднева Г.И., Белов Б.С., Аронова Е.С. Реактивация хронического гепатита В у пациентки с ревматоидным артритом. Эффективная фармакотерапия. 2023;19(9):6-11 [Gridneva GI, Belov BS, Aronova ES. Reactivation of Chronic Hepatitis B in a Patient with Rheumatoid Arthritis. Effective pharmacotherapy. 2023;19(9):6-11 (in Russian)]. DOI:10.33978/2307-3586-2023-19-9-6-11
46. Белов Б.С., Абдурахманов Д.Т. Вирус гепатита В и ревматические болезни. Научно-практическая ревматология. 2020;58(2):207-13 [Belov BS, Abdurakhmanov DT. Hepatitis B virus and rheumatic diseases. Rheumatology Science and Practice. 2020;58(2):207-13 (in Russian)]. DOI:10.14412/1995-4484-2020-207-213
47. Sagnelli C, Montella L, Grimaldi P, et al. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens. 2022;11(7). DOI:10.3390/pathogens11070816
48. Foo H, Phan F, Bagatella M, et al. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19. Eur J Clin Microbiol Infect Dis. 2023;42(6):799-801. DOI:10.1007/s10096-023-04599-5
49. Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89-94. DOI:10.1111/jvh.13410
50. Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol.
2022;11(5):275-82. DOI:10.5501/wjv.v11.i5.275
51. Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021;27(19):2312-24. DOI:10.3748/wjg.v27.i19.2312
52. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-23. DOI:10.1002/art.41752
53. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol. 2017;67:370-98. DOI:10.1016/j.jhep.2017.03.021
54. Onorato L, Pisaturo M, Camaioni C, et al. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med. 2021;10(21). DOI:10.3390/jcm10215201
55. Chen YL, Lin JZ, Mo YQ, et al. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Arthritis Res Ther. 2018;20(1):81. DOI:10.1186/s13075-018-1548-5
56. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;3:58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):58-88 (in Russian)].
57. Yuan C, Peng J, Xia R, et al. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol. 2022;13:865124. DOI:10.3389/fmicb.2022.865124
58. Zhang L, Yang S, Yu Y, et al. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun. 2022;6(9):2431-40. DOI:10.1002/hep4.1994
59. Alnaqbi KA, Hannawi S, Namas R, et al. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. Int J Rheum Dis. 2022;25(10):1107-22. DOI:10.1111/1756-185X.14406
60. Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444-55. DOI:10.3748/wjg.v22.i28.6444
61. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
2. Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2023;43(3):523-31. DOI:10.1007/s00296-022-05169-2
3. О Всемирном дне борьбы с вирусными гепатитами: информация Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 28.07.2022. Режим доступа: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Ссылка активна на 29.04.2023 [O Vsemirnom dne bor'by s virusnymi gepatitami: informatsiia Federal'noi sluzhby po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiia cheloveka ot 28.07.2022. Available at: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Accessed: 29.04.2023 (in Russian)].
4. Каратеев А.Е., Гонтаренко Н.В., Цурган А.В., и др. Вирусные гепатиты B и C как коморбидная патология при ревматических заболеваниях: анализ данных клиники ФГБНУ НИИР им. В.А. Насоновой за 4 года. Научно-практическая ревматология. 2016;54(3):318-23 [Karateev AE, Gontarenko NV, Tsurgan AV, et al. Viral hepatitis B and C as comorbidity in rheumatic diseases: Analysis of the data of the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. Rheumatology Science and Practice. 2016;54(3):318-23 (in Russian)]. DOI:10.14412/1995-4484-2016-318-323
5. Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020;8(11). DOI:10.3390/microorganisms8111792
6. Makvandi M, Noormandi Pour S, Teimoori A, et al. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran. Asian Pac J Cancer Prev. 2022;23(6):1921-6. DOI:10.31557/APJCP.2022.23.6.1921
7. Lo Presti A, Ceccarelli F, Dorrucci M, et al. Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus. New Microbiol. 2022;45(4):296-303.
8. Min Y, Wei X, Xia X, et al. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023;14:1141956. DOI:10.3389/fimmu.2023.1141956
9. Ramsey SD, Unger JM, Baker LH, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497-505. DOI:10.1001/jamaoncol.2018.6437
10. Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-53. DOI:10.1136/ard-2022-223335
11. Padda IS, Bhatt R, Parmar M. Upadacitinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
12. Lin TC, Hashemi N, Kim SC, et al. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2018;70(1):30-8. DOI:10.1002/acr.23241
13. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. DOI:10.1002/hep.29800
14. Fujita M, Sugiyama M, Sato Y, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat.
2018;25(11):1312-20. DOI:10.1111/jvh.12933
15. Mohareb AM, Patel NJ, Fu X, et al. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2022;49(1):104-9. DOI:10.3899/jrheum.210257
16. Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8. DOI:10.1016/j.jmii.2017.10.002
17. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3. DOI:10.1053/j.gastro.2014.10.038
18. Zhou Q, Zhang Q, Wang K, et al. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacol Res. 2022;178:106181. DOI:10.1016/j.phrs.2022.106181
19. Verdelli A, Corrà A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:941003. DOI:10.3389/fmed.2022.941003
20. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-75. DOI:10.1007/s10067-012-1988-2
21. Kalyoncu U, Yonem O, Calguneri M, et al. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatol Int. 2009;29(7):777-80. DOI:10.1007/s00296-008-0790-6
22. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36(6):1188-94. DOI:10.3899/jrheum.081246
23. Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021;24(11):1362-9. DOI:10.1111/1756-185X.14217
24. Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med. 2021;10(12). DOI:10.3390/jcm10122564
25. Xuan D, Yu Y, Shao L, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577-86. DOI:10.1007/s10067-013-2450-9
26. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immuno- suppressive drug therapy. Gastroenterology. 2015;148(1):215-9;quiz e16-7. DOI:10.1053/j.gastro.2014.10.039
27. Zhong Z, Liao W, Dai L, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis. 2022;81(4):584-91. DOI:10.1136/annrheumdis-2021-221650
28. Гриднева Г.И., Белов Б.С., Аронова Е.С. Хронический вирусный гепатит В и ревматические болезни: современный взгляд на проблему. Медицинский алфавит. 2022;29:20-8 [Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: modern view on problem. Medical Alphabet. 2022;29:20-8 (in Russian)]. DOI:10.33667/2078-5631-2022-22-20-28
29. Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780-2. DOI:10.1136/annrheumdis-2017-211322
30. Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1). DOI:10.1136/rmdopen-2019-001095
31. Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases. 2022;10(1):12-22. DOI:10.12998/wjcc.v10.i1.12
32. Lin YC, Chen YJ, Lee SW, et al. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med. 2021;10(15). DOI:10.3390/jcm10153296
33. Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98(9):829-34. DOI:10.2340/00015555-2989
34. Kuo MH, Tseng CW, Lu MC, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;66(11):4026-34. DOI:10.1007/s10620-020-06725-1
35. Lin WT, Chen YM, Chen DY, et al. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75. DOI:10.1177/0961203317711009
36. Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. DOI:10.1177/1759720X20912646
37. Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11(2):e780. DOI:10.1002/iid3.780
38. Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021;9(21):5769-81. DOI:10.12998/wjcc.v9.i21.5769
39. Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670-89. DOI:10.1016/j.jhep.2022.07.003
40. Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015;14(6):979-85. DOI:10.1517/14740338.2015.1031743
41. Koutsianas C, Hadziyannis E, Thomas K, et al. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021;28(12):1710-8. DOI:10.1111/jvh.13610
42. Kuo MH, Tseng CW, Lee CH, et al. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep. 2020;10(1):2456. DOI:10.1038/s41598-020-59406-4
43. Lan TY, Lin YC, Tseng TC, et al. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut Liver. 2023;17(2):288-98. DOI:10.5009/gnl210551
44. Ridola L, Zullo A, Laganà B, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57(3):244-8. DOI:10.4415/ANN_21_03_08
45. Гриднева Г.И., Белов Б.С., Аронова Е.С. Реактивация хронического гепатита В у пациентки с ревматоидным артритом. Эффективная фармакотерапия. 2023;19(9):6-11 [Gridneva GI, Belov BS, Aronova ES. Reactivation of Chronic Hepatitis B in a Patient with Rheumatoid Arthritis. Effective pharmacotherapy. 2023;19(9):6-11 (in Russian)]. DOI:10.33978/2307-3586-2023-19-9-6-11
46. Белов Б.С., Абдурахманов Д.Т. Вирус гепатита В и ревматические болезни. Научно-практическая ревматология. 2020;58(2):207-13 [Belov BS, Abdurakhmanov DT. Hepatitis B virus and rheumatic diseases. Rheumatology Science and Practice. 2020;58(2):207-13 (in Russian)]. DOI:10.14412/1995-4484-2020-207-213
47. Sagnelli C, Montella L, Grimaldi P, et al. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens. 2022;11(7). DOI:10.3390/pathogens11070816
48. Foo H, Phan F, Bagatella M, et al. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19. Eur J Clin Microbiol Infect Dis. 2023;42(6):799-801. DOI:10.1007/s10096-023-04599-5
49. Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89-94. DOI:10.1111/jvh.13410
50. Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol.
2022;11(5):275-82. DOI:10.5501/wjv.v11.i5.275
51. Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021;27(19):2312-24. DOI:10.3748/wjg.v27.i19.2312
52. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-23. DOI:10.1002/art.41752
53. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol. 2017;67:370-98. DOI:10.1016/j.jhep.2017.03.021
54. Onorato L, Pisaturo M, Camaioni C, et al. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med. 2021;10(21). DOI:10.3390/jcm10215201
55. Chen YL, Lin JZ, Mo YQ, et al. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Arthritis Res Ther. 2018;20(1):81. DOI:10.1186/s13075-018-1548-5
56. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;3:58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):58-88 (in Russian)].
57. Yuan C, Peng J, Xia R, et al. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol. 2022;13:865124. DOI:10.3389/fmicb.2022.865124
58. Zhang L, Yang S, Yu Y, et al. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun. 2022;6(9):2431-40. DOI:10.1002/hep4.1994
59. Alnaqbi KA, Hannawi S, Namas R, et al. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. Int J Rheum Dis. 2022;25(10):1107-22. DOI:10.1111/1756-185X.14406
60. Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444-55. DOI:10.3748/wjg.v22.i28.6444
61. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
________________________________________________
1. Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol. 2022;49(1):1-4. DOI:10.3899/jrheum.211000
2. Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2023;43(3):523-31. DOI:10.1007/s00296-022-05169-2
3. O Vsemirnom dne bor'by s virusnymi gepatitami: informatsiia Federal'noi sluzhby po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiia cheloveka ot 28.07.2022. Available at: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Accessed: 29.04.2023 (in Russian).
4. Karateev AE, Gontarenko NV, Tsurgan AV, et al. Viral hepatitis B and C as comorbidity in rheumatic diseases: Analysis of the data of the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. Rheumatology Science and Practice. 2016;54(3):318-23 (in Russian). DOI:10.14412/1995-4484-2016-318-323
5. Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020;8(11). DOI:10.3390/microorganisms8111792
6. Makvandi M, Noormandi Pour S, Teimoori A, et al. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran. Asian Pac J Cancer Prev. 2022;23(6):1921-6. DOI:10.31557/APJCP.2022.23.6.1921
7. Lo Presti A, Ceccarelli F, Dorrucci M, et al. Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus. New Microbiol. 2022;45(4):296-303.
8. Min Y, Wei X, Xia X, et al. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023;14:1141956. DOI:10.3389/fimmu.2023.1141956
9. Ramsey SD, Unger JM, Baker LH, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497-505. DOI:10.1001/jamaoncol.2018.6437
10. Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-53. DOI:10.1136/ard-2022-223335
11. Padda IS, Bhatt R, Parmar M. Upadacitinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
12. Lin TC, Hashemi N, Kim SC, et al. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2018;70(1):30-8. DOI:10.1002/acr.23241
13. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. DOI:10.1002/hep.29800
14. Fujita M, Sugiyama M, Sato Y, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat.
2018;25(11):1312-20. DOI:10.1111/jvh.12933
15. Mohareb AM, Patel NJ, Fu X, et al. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2022;49(1):104-9. DOI:10.3899/jrheum.210257
16. Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8. DOI:10.1016/j.jmii.2017.10.002
17. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3. DOI:10.1053/j.gastro.2014.10.038
18. Zhou Q, Zhang Q, Wang K, et al. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacol Res. 2022;178:106181. DOI:10.1016/j.phrs.2022.106181
19. Verdelli A, Corrà A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:941003. DOI:10.3389/fmed.2022.941003
20. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-75. DOI:10.1007/s10067-012-1988-2
21. Kalyoncu U, Yonem O, Calguneri M, et al. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatol Int. 2009;29(7):777-80. DOI:10.1007/s00296-008-0790-6
22. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36(6):1188-94. DOI:10.3899/jrheum.081246
23. Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021;24(11):1362-9. DOI:10.1111/1756-185X.14217
24. Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med. 2021;10(12). DOI:10.3390/jcm10122564
25. Xuan D, Yu Y, Shao L, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577-86. DOI:10.1007/s10067-013-2450-9
26. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immuno- suppressive drug therapy. Gastroenterology. 2015;148(1):215-9;quiz e16-7. DOI:10.1053/j.gastro.2014.10.039
27. Zhong Z, Liao W, Dai L, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis. 2022;81(4):584-91. DOI:10.1136/annrheumdis-2021-221650
28. Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: modern view on problem. Medical Alphabet. 2022;29:20-8 (in Russian).
DOI:10.33667/2078-5631-2022-22-20-28
29. Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780-2. DOI:10.1136/annrheumdis-2017-211322
30. Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1). DOI:10.1136/rmdopen-2019-001095
31. Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases. 2022;10(1):12-22. DOI:10.12998/wjcc.v10.i1.12
32. Lin YC, Chen YJ, Lee SW, et al. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med. 2021;10(15). DOI:10.3390/jcm10153296
33. Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98(9):829-34. DOI:10.2340/00015555-2989
34. Kuo MH, Tseng CW, Lu MC, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci.
2021;66(11):4026-34. DOI:10.1007/s10620-020-06725-1
35. Lin WT, Chen YM, Chen DY, et al. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75. DOI:10.1177/0961203317711009
36. Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. DOI:10.1177/1759720X20912646
37. Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11(2):e780. DOI:10.1002/iid3.780
38. Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021;9(21):5769-81. DOI:10.12998/wjcc.v9.i21.5769
39. Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670-89. DOI:10.1016/j.jhep.2022.07.003
40. Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015;14(6):979-85. DOI:10.1517/14740338.2015.1031743
41. Koutsianas C, Hadziyannis E, Thomas K, et al. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021;28(12):1710-8. DOI:10.1111/jvh.13610
42. Kuo MH, Tseng CW, Lee CH, et al. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep. 2020;10(1):2456. DOI:10.1038/s41598-020-59406-4
43. Lan TY, Lin YC, Tseng TC, et al. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut Liver. 2023;17(2):288-98. DOI:10.5009/gnl210551
44. Ridola L, Zullo A, Laganà B, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57(3):244-8. DOI:10.4415/ANN_21_03_08
45. Gridneva GI, Belov BS, Aronova ES. Reactivation of Chronic Hepatitis B in a Patient with Rheumatoid Arthritis. Effective pharmacotherapy. 2023;19(9):6-11 (in Russian). DOI:10.33978/2307-3586-2023-19-9-6-11
46. Belov BS, Abdurakhmanov DT. Hepatitis B virus and rheumatic diseases. Rheumatology Science and Practice. 2020;58(2):207-13 (in Russian).
DOI:10.14412/1995-4484-2020-207-213
47. Sagnelli C, Montella L, Grimaldi P, et al. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens. 2022;11(7). DOI:10.3390/pathogens11070816
48. Foo H, Phan F, Bagatella M, et al. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19. Eur J Clin Microbiol Infect Dis. 2023;42(6):799-801. DOI:10.1007/s10096-023-04599-5
49. Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89-94. DOI:10.1111/jvh.13410
50. Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol.
2022;11(5):275-82. DOI:10.5501/wjv.v11.i5.275
51. Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021;27(19):2312-24. DOI:10.3748/wjg.v27.i19.2312
52. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-23. DOI:10.1002/art.41752
53. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol. 2017;67:370-98. DOI:10.1016/j.jhep.2017.03.021
54. Onorato L, Pisaturo M, Camaioni C, et al. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med. 2021;10(21). DOI:10.3390/jcm10215201
55. Chen YL, Lin JZ, Mo YQ, et al. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Arthritis Res Ther. 2018;20(1):81. DOI:10.1186/s13075-018-1548-5
56. Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):58-88 (in Russian).
57. Yuan C, Peng J, Xia R, et al. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol. 2022;13:865124. DOI:10.3389/fmicb.2022.865124
58. Zhang L, Yang S, Yu Y, et al. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun. 2022;6(9):2431-40. DOI:10.1002/hep4.1994
59. Alnaqbi KA, Hannawi S, Namas R, et al. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. Int J Rheum Dis. 2022;25(10):1107-22. DOI:10.1111/1756-185X.14406
60. Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444-55. DOI:10.3748/wjg.v22.i28.6444
61. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. DOI:10.1038/s41584-022-00798-0
Авторы
Г.И. Гриднева*, Б.С. Белов, Е.С. Аронова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
*gigridneva@mail.ru
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
*gigridneva@mail.ru
________________________________________________
Galina I. Gridneva*, Boris S. Belov, Evgeniia S. Aronova
Nasonova Research Institute of Rheumatology, Moscow, Russia
*gigridneva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.